Non-tuberculous Mycobacteria (NTM) infections present a significant public health concern globally. NTM, unlike tuberculosis, aren’t transmitted from person to person. However, they can cause severe lung disease, particularly in individuals with pre-existing respiratory conditions. Accurate diagnosis and effective treatment are vital in managing these infections.
With an increasing number of cases each year, understanding NTM treatment becomes crucial. This comprehensive guide explores various NTM medications, their dosages, and potential side effects.
NTM Medication: Rifampicin
Rifampicin, an antibiotic, stands as a cornerstone in NTM treatment. It obstructs the protein synthesis of bacteria, disabling their growth. Generally, the dosage ranges from 10 to 20 mg/kg daily. However, physicians should individualize the dosage considering the patient’s condition. Potential side effects include nausea, vomiting, and hepatotoxicity.
NTM Treatment: Macrolides
Macrolides, like azithromycin and clarithromycin, are fundamental to NTM treatment. They work by inhibiting protein synthesis in bacteria, thereby stunting their growth.
Azithromycin’s typical dose ranges from 250 to 500 mg per day, while clarithromycin ranges from 500 to 1000 mg daily. The common side effects include abdominal discomfort, nausea, and potential QT interval prolongation.
NTM Medication: Isoniazid
Isoniazid is another key antibiotic used in NTM treatment. It inhibits mycolic acid synthesis, which is crucial to mycobacterial cell wall structure. The usual dose ranges from 5 to 10 mg/kg/day. Side effects may include peripheral neuropathy and, rarely, hepatotoxicity.
NTM Treatment: Ethambutol
Ethambutol, an antimycobacterial agent, works by disrupting the cell wall synthesis of mycobacteria. The general dose is 15 to 25 mg/kg daily. This drug can lead to side effects like optic neuritis and peripheral neuropathy.
Clofazimine for NTM
Clofazimine is a dye that also possesses anti-inflammatory and antibacterial properties. The usual dose is 100 to 200 mg daily. Potential side effects include skin discoloration and gastrointestinal complaints.
Nebulised Amikacin for NTM
Nebulised amikacin, an aminoglycoside antibiotic, delivers a high concentration of the drug directly to the lungs, making it highly effective against NTM. Typical doses vary from 250 to 500 mg daily. It may cause side effects like voice hoarseness and coughing.
Introducing Liposomal Amikacin (Arikayce)
Arikayce, the liposomal form of amikacin, encapsulates the antibiotic in tiny fat-like particles. This formulation optimises the drug’s delivery into the lungs, allowing for deeper penetration into the infected tissues and enhancing the drug’s efficacy.
Arikayce is particularly promising for patients with refractory NTM lung disease caused by Mycobacterium avium complex (MAC), a common NTM species. This treatment is especially beneficial for those patients who have failed to respond to standard multidrug regimens.
Evidence Supporting Arikayce in Refractory NTM
Clinical trials have provided promising data on Arikayce’s role in treating refractory NTM. The CONVERT study, a pivotal Phase 3 trial, found that adding Arikayce to guideline-based therapy significantly increased the proportion of refractory NTM patients achieving culture conversion (clearance of NTM from the lungs) compared to guideline-based therapy alone.
Moreover, most patients who achieved culture conversion sustained this benefit over six months, highlighting Arikayce’s lasting impact. These results led to Arikayce’s approval for refractory NTM lung disease caused by MAC in several countries.
Like all medications, Arikayce can cause side effects, most commonly respiratory events such as cough, dysphonia, and dyspnea. Therefore, clinicians should carefully weigh the benefits and risks when considering this therapy.
Co-trimoxazole in NTM Treatment
Co-trimoxazole, also an antibiotic, interferes with the bacterial synthesis of folic acid. The dosage is usually 960 mg twice daily. Common side effects include rash, nausea, and potential kidney complications.
Intravenous Medications for NTM
For severe NTM infections, IV meropenem, IV imipenem, and IV tigecycline may be required.
Meropenem and imipenem, carbapenem antibiotics, disrupt bacterial cell wall synthesis. Typical doses for meropenem are 1g every 8 hours, and for imipenem, 500mg to 1g every 6 to 8 hours. Common side effects are gastrointestinal discomfort and potential seizures.
Tigecycline, a broad-spectrum antibiotic, impedes bacterial protein synthesis. The usual dose is 50 mg every 12 hours, following a 100 mg initial dose. It may cause nausea, vomiting, and diarrhoea.
Side Effects Management in NTM Treatment
While NTM medication forms an essential pillar of infection management, monitoring for potential side effects is equally vital. Renal and liver function tests, audiology assessments, and vigilant symptom tracking are key aspects of this monitoring process.
Monitoring for side effects in NTM treatment helps prevent serious complications, optimise drug effectiveness, and maintain patient safety. Regular monitoring fosters prompt detection and management of side effects, ensuring the continuation of effective treatment.
Renal function monitoring in NTM treatment
Many NTM medications can affect kidney function, making renal function tests a must. These tests evaluate how well the kidneys filter waste products from your blood.
Patients on aminoglycosides like amikacin, co-trimoxazole, or intravenous medications such as meropenem, imipenem, or tigecycline may need more frequent monitoring due to their potential nephrotoxicity. Regular renal function tests help to identify early signs of kidney impairment, allowing for prompt intervention.
Liver function monitoring in NTM treatment
Several NTM medications, including rifampicin, isoniazid, and macrolides, can affect liver function. Consequently, liver function tests, which measure various enzymes and proteins in your blood, are crucial in patients undergoing NTM treatment.
By monitoring the liver enzymes, healthcare providers can detect early signs of drug-induced liver injury and take necessary actions, such as dose adjustment or drug substitution, to prevent severe liver damage.
Audiology assessment
NTM medications, particularly aminoglycosides like amikacin, may affect hearing. Therefore, patients on these medications should undergo regular audiology assessments.
These assessments identify any potential ototoxicity – damage to the ear or nerve supply by medications. Early detection allows clinicians to adjust the treatment plan to prevent further hearing loss while continuing to effectively treat the NTM infection.
Symptom tracking and other assessments
Apart from these specific tests, healthcare providers should also monitor patients for any new symptoms or side effects. This can be as simple as asking the patient how they feel, to more elaborate assessments like skin examinations for clofazimine-induced skin discoloration, or ECG monitoring for QT interval prolongation with macrolides.
NTM Treatment Regimens: Guideline based but Personalization is Key
NTM treatment often requires a multidrug approach, leveraging the synergy of these medications. The specifics of the regimen depend on various factors, including the type of NTM, the patient’s overall health status, and the presence of any resistance to the medications.
Although the treatment is based on current published guidelines, it is common to see a combination of macrolides, rifampicin, and ethambutol used. However, depending on the isolated mycobacterium and cases of drug intolerance or resistance, a respiratory infection specialist may choose to include isoniazid, clofazimine, or nebulised amikacin. In severe cases, or in the initiation phase of treatment for Mycobacterium abscessus, intravenous medications like meropenem, imipenem, or tigecycline may be necessary.
Conclusion: NTM Treatment
Effectively treating NTM infection is a long journey that requires a well-thought-out treatment strategy and close monitoring of the patient’s condition. The medications discussed above offer a robust arsenal for healthcare providers to combat NTM. By understanding these drugs and their side effects, patients can better participate in their treatment planning, leading to better health outcomes.
Though NTM infection is a significant health issue, we have effective NTM medications in our toolkit. With ongoing research, we can look forward to even more refined and potent treatment strategies.
GET IN TOUCH
Schedule a Visit
Disclaimer: The information provided in this article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition or treatment.